Tests desloratadine with mesalamine for ulcerative colitis in adults
Tests desloratadine added to mesalamine in adults with mild to moderate ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Desloratadine in Patients With Ulcerative Colitis
Key facts
- Where
- Shibīn al Kawm, EgyptSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with active mild or moderate ulcerative colitis who are already treated with 5-aminosalisylic acid (mesalamine).
- Age
- 18 to 65 years
- Sex
- Both men and women can join.
- Disease stage
- Active mild or moderate ulcerative colitis, as defined by the American College of Gastroenterology (ACG) Clinical Guideline.
- Earlier treatment
- People must be treated with 5-aminosalisylic acid (mesalamine). People on systemic or rectal steroids, immunosuppressants or biological therapies cannot join.
Main reasons for not taking part
- Severe ulcerative colitis
- Significant liver or kidney function problems
- Pregnant or breastfeeding women
- Known allergy to desloratadine or any ingredient in it
- Other inflammatory diseases, history of colon cancer, or complete or partial colectomy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07333716, who can take part
Where in Egypt
- Menofia university HospitalsShibīn al Kawm, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT07333716
- Record updated
- 29 January 2026
- Original description
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.Read full original descriptionShow less
Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
Inclusion: Both male and female sex; patients with age ranged from 18 to 65; patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline; Patients treated with 5-aminosalisylic acid (mesalamine).
Exclusion: Treatment with systemic or rectal steroids; Treatment with immunosuppressant or biological therapies; Known allergy to desloratadine or any ingredient in the formulation; Patients with other inflammatory diseases; Patients with history of colon cancer; Patients with severe UC; Significant liver or kidney function abnormalities; Pregnant or lactating females; Patients with complete or partial colectomy.